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October 12, 2010:1352–6The validity of the observation that dronedarone reduces car-
iovascular hospitalization would have been strengthened if the
rial had documented systematically the underlying reasons for
ospitalizations (typically hemodynamic instability, exacerbation
f heart failure, anticoagulation, or cardioversion) and the expected
ttendant improvement in symptom status and quality of life.
oupled with the lack of external adjudication (that minimizes the
ulnerability to cardiovascular versus noncardiovascular misclassi-
cation errors, particularly in trials that span geographic regions
nd clinical practice settings) (3,4) and the exploratory nature of
he analysis (given the pre-specified hierarchical sequential plan),
hese limitations serve not only to undermine the clinical relevance
f this finding, but also to raise questions about the overall quality
f the data, and ultimately the reliability of the findings.
The original report mentions 1 amendment dated March 8, 2006,
o alter the enrollment criterion to include older subjects (2). No
urther protocol changes are mentioned, including the amendment
ated August 25, 2006, to increase the sample size from 3,700 to
,300, nor is any reason given for the extension of the sample size
rom 4,300 to 4,628. We do not doubt these protocol changes were
one blindly, without knowledge of any emerging treatment effects.
owever, we are intrigued that investigators stopped at 255 deaths,
short of achieving the protocol-specified goal of 260 deaths.
onetheless, these protocol changes should have been reported in a
ransparent manner and appropriate caution should have been urged
n interpreting cardiovascular death results as being exploratory, given
he rules of engagement of a hierarchical sequential analysis plan.
nstead, the published conclusion that the drug reduced cardiovascular
eaths is highly misleading, when in reality that benefit was not
ignificant under the original plan (1). Although no malfeasance is
mplied, we nonetheless feel strongly that changing rules in the middle
f the trial is antithetical to the principles of good clinical trial practice.
oreover, the mechanisms that underlie dronedarone’s reduction of
ardiovascular death remain unclear. Death resulting from stroke,
entricular arrhythmia, or heart failure was not impacted favorably by
ronedarone (2). Did the associated reductions in acute coronary
yndromes—a post-hoc observation—account for this finding, or was
his merely the play of chance? In the end, the ATHENA trial was
ot designed to answer these questions, and the observed reduction in
ardiovascular death is at best exploratory and hypothesis generating,
equiring confirmation in subsequent studies.
The authors have raised issues with our meta-analysis. The
bjective was not solely to estimate an overall measure of effect (a
ynthesis-centric goal), where it is appropriate to question whether
ertain studies should be combined, but rather to explore the rea-
ons for differences between the studies (an analysis-centric goal) to
lace the evidence in its proper context. The results are insightful
ecause they provide reassurance about dronedarone’s safety in the
arget population (1). The weighting is described in the figure legend
1), and adjusting for patient-years of exposure did not materially
hange the summary relative risk estimate. Finally, we acknowledge
he typographical error regarding the mean follow-up in the
NDROMEDA (ANti-arrhythmic trial with DROnedarone in
oderate to severe congestive heart failure Evaluating morbidity
ecreAse) trial, which had no impact on our analysis.
Rather than missing the forest for the trees, we present the evi-
ence in an objective and unembellished manner. Although the truth
an be determined by each reader, the plain fact, in our opinion, is that
ronedarone has very modest efficacy as an antiarrhythmic agent, and
ased on the current evidence, its use for the treatment of nonper-
anent atrial fibrillation or atrial flutter can be supported only as a recond- or third-line agent in individuals who are not able to tolerate
miodarone or other first-line agents recommended by the guidelines.
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he Concept of the
etabolic Syndrome
s It Dead Yet?
he main finding of the case-control study by Mente et al. (1) is that
he risk of myocardial infarction associated with the diagnosis of
etabolic syndrome (MS) is no greater than that of the sum of its
ndividual components. However, this interpretation is solely based on
finding of similar effect sizes (odds ratio) associated with MS and
reviously diagnosed (and/or treated) diabetes mellitus or hyperten-
ion. The authors note that, in this study (as in many other studies),
oth hypertension and diabetes frequently coexisted. Moreover, they
uggest that the patients with hypertension or diabetes were more
ikely to have at least 1 additional component of MS present (most
ommonly, central obesity: 71%). Therefore, it is not surprising that
he odds ratio associated with each of them in separate regression
odels was found to be similar to that obtained by the use of MS, as
atients with both diabetes and hypertension also had clustering of
ther individual components. We believe it would be more informa-
ive to describe the effect sizes associated with those with only diabetes
r only hypertension, when comparing them with those associated
ith the presence of MS. However, to assess whether the sum of the
isk associated with individual components is greater than that
ssociated with the presence of MS, it may be better to estimate the
isk of myocardial infarction associated with MS, after adjusting for all
ts individual components (when used as continuous variables) in a
egression model.
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1356 Correspondence JACC Vol. 56, No. 16, 2010
October 12, 2010:1352–6Furthermore, a review of current literature suggests that the
pproach of using only effect sizes when comparing the utility of
isk factors may be obsolete—particularly in light of more efficient
tatistical approaches such as net reclassification index and incre-
ental discrimination index (2,3)—the techniques that enable
omparisons based on number of subjects correctly allocated with
he enhanced risk or not.
However, we agree that despite these further analyses, the eventual
nterpretation may remain unchanged, as evidenced by findings of a
ecent study (4) among 19,000 hypertensive patients, where there
as an absence of any synergy among the individual components of
S on the risk of coronary outcomes associated with MS. However,
n that study, the risk of stroke and all-cause mortality associated with
S, independent of its components, was found to be significant. We
elieve these apparent contradictions in the current literature are likely
o be minimized by interrogating prospective data, to evaluate
hether the risk of myocardial infarction (both in terms of magnitude
nd the number of patients correctly identified) is more closely
ssociated with MS or with the presence of each of the individual risk
actors, separately and in combination.
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eply
rs. Gupta and Poulter raise an interesting point about our study (1)
nd about estimating the risk of myocardial infarction (MI) associated
ith metabolic syndrome (MS), after adjusting for all its individual
omponents (as continuous variables). The idea of controlling for all
omponents and MS simultaneously to assess each of the effects
omparatively seems intuitive. However, there are statistical assump-
ions in constructing such a model. Controlling for component factors
hat were used to define MS would likely substantially alter the
ssociation between MS and MI risk. Indeed, when adjusting for all
f the individual MS components, the odds of MS on MI risk is 1
odds ratio: 0.79; 95% confidence interval: 0.68 to 0.91); however, theffects of diabetes mellitus (odds ratio: 2.52; 95% confidence interval:
.24 to 2.83) and hypertension (odds ratio: 2.22; 95% confidence
nterval: 2.05 to 2.39) remain robust after simultaneous adjustment.
rior investigations have used a similar approach to that of our study
n assessing the effects of MS and component factors (2,3).
We agree that alternative analytical approaches may be used to
etermine the agreement between MS and component factors clas-
ification versus MI (e.g., net reclassification). However, this approach
s usually applied to prospective cohort data, and not to retrospective
ase-control data. Nonetheless, as the investigators recognize, the
eneral pattern of results and eventual interpretation is unlikely to
hange. Moreover, an important advantage of estimating the effect
ize is that it may be used to estimate population attributable risk
PAR), an approach used previously in the first INTERHEART
tudy (a global case-control study of risk factors for acute myocardial
nfarction) paper, which showed that 90% of risk of MI is explained
y 9 modifiable risk factors (4). An assessment of the PAR of MS on
I is particularly important in the current study, since the use of a
ichotomous definition of MS based on 3 risk factors leads to a
ubstantially lower prevalence of MS than its component factors (e.g.,
0% for MS compared with 19.6% for diabetes and 23.4% for
ypertension). This finding partly explains our observation that the
AR of MS is substantially lower than the PAR of several component
actors considered separately, including diabetes and hypertension,
nd indicates that MS accounts for a smaller number of MI cases in
population compared with several of its constituent components.
hus, our findings highlight an important limitation of MS diagnosis.
We also agree that a cohort study might provide more rigorous
ata. However, an important strength of the INTERHEART study
s that it is a large international study of 52 countries using a stan-
ardized protocol, and it is the first large study to show that the risk
f MI associated with MS is qualitatively similar across sex, global
egions, and ethnic groups. A cohort study with similar objectives
ould require an enormous sample size and 2 decades of follow-up.
lthough not impossible, such a study would be extremely costly to
onduct.
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